291 related articles for article (PubMed ID: 25506896)
21. Adiponectin as a potential tumor suppressor inhibiting epithelial-to-mesenchymal transition but frequently silenced in prostate cancer by promoter methylation.
Tan W; Wang L; Ma Q; Qi M; Lu N; Zhang L; Han B
Prostate; 2015 Aug; 75(11):1197-205. PubMed ID: 25877612
[TBL] [Abstract][Full Text] [Related]
22. CX3CL1 increases invasiveness and metastasis by promoting epithelial-to-mesenchymal transition through the TACE/TGF-α/EGFR pathway in hypoxic androgen-independent prostate cancer cells.
Tang J; Xiao L; Cui R; Li D; Zheng X; Zhu L; Sun H; Pan Y; Du Y; Yu X
Oncol Rep; 2016 Feb; 35(2):1153-62. PubMed ID: 26718770
[TBL] [Abstract][Full Text] [Related]
23. Epithelial-mesenchymal transition in prostate cancer is associated with quantifiable changes in nuclear structure.
Verdone JE; Parsana P; Veltri RW; Pienta KJ
Prostate; 2015 Feb; 75(2):218-24. PubMed ID: 25327565
[TBL] [Abstract][Full Text] [Related]
24. MiR-573 inhibits prostate cancer metastasis by regulating epithelial-mesenchymal transition.
Wang L; Song G; Tan W; Qi M; Zhang L; Chan J; Yu J; Han J; Han B
Oncotarget; 2015 Nov; 6(34):35978-90. PubMed ID: 26451614
[TBL] [Abstract][Full Text] [Related]
25. [Characterization of prostate cancer cell lines and their epithelial-mesenchymal transition in subcutaneous tumors].
Zhao L; Jiang YG; Ma J; Luo Y; Zhao JH
Zhonghua Nan Ke Xue; 2011 Apr; 17(4):314-7. PubMed ID: 21548207
[TBL] [Abstract][Full Text] [Related]
26. βKlotho inhibits androgen/androgen receptor‑associated epithelial‑mesenchymal transition in prostate cancer through inactivation of ERK1/2 signaling.
Liu Z; Zhang H; Ding S; Qi S; Liu S; Sun D; Dong W; Yin L; Li M; Zhao X; Lu J
Oncol Rep; 2018 Jul; 40(1):217-225. PubMed ID: 29749458
[TBL] [Abstract][Full Text] [Related]
27. The metastasis suppressor CD82/KAI1 inhibits fibronectin adhesion-induced epithelial-to-mesenchymal transition in prostate cancer cells by repressing the associated integrin signaling.
Lee J; Byun HJ; Lee MS; Jin YJ; Jeoung D; Kim YM; Lee H
Oncotarget; 2017 Jan; 8(1):1641-1654. PubMed ID: 27926483
[TBL] [Abstract][Full Text] [Related]
28. The FABP12/PPARγ pathway promotes metastatic transformation by inducing epithelial-to-mesenchymal transition and lipid-derived energy production in prostate cancer cells.
Liu RZ; Choi WS; Jain S; Dinakaran D; Xu X; Han WH; Yang XH; Glubrecht DD; Moore RB; Lemieux H; Godbout R
Mol Oncol; 2020 Dec; 14(12):3100-3120. PubMed ID: 33031638
[TBL] [Abstract][Full Text] [Related]
29. SSX2 regulates focal adhesion but does not drive the epithelial to mesenchymal transition in prostate cancer.
Bloom JE; McNeel DG
Oncotarget; 2016 Aug; 7(32):50997-51011. PubMed ID: 27276714
[TBL] [Abstract][Full Text] [Related]
30. Epithelial-to-mesenchymal transition in prostate cancer: paradigm or puzzle?
Nauseef JT; Henry MD
Nat Rev Urol; 2011 Jun; 8(8):428-39. PubMed ID: 21691304
[TBL] [Abstract][Full Text] [Related]
31. HIC1 loss promotes prostate cancer metastasis by triggering epithelial-mesenchymal transition.
Hao M; Li Y; Wang J; Qin J; Wang Y; Ding Y; Jiang M; Sun X; Zu L; Chang K; Lin G; Du J; Korinek V; Ye DW; Wang J
J Pathol; 2017 Aug; 242(4):409-420. PubMed ID: 28466555
[TBL] [Abstract][Full Text] [Related]
32. [Epithelial mesenchymal transition in prostate cancer: Advances in current research].
Yan B; Jiang N; Niu YJ
Zhonghua Nan Ke Xue; 2015 Sep; 21(9):847-51. PubMed ID: 26552221
[TBL] [Abstract][Full Text] [Related]
33. Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy.
Sun Y; Wang BE; Leong KG; Yue P; Li L; Jhunjhunwala S; Chen D; Seo K; Modrusan Z; Gao WQ; Settleman J; Johnson L
Cancer Res; 2012 Jan; 72(2):527-36. PubMed ID: 22108827
[TBL] [Abstract][Full Text] [Related]
34. Berberine inhibits the metastatic ability of prostate cancer cells by suppressing epithelial-to-mesenchymal transition (EMT)-associated genes with predictive and prognostic relevance.
Liu CH; Tang WC; Sia P; Huang CC; Yang PM; Wu MH; Lai IL; Lee KH
Int J Med Sci; 2015; 12(1):63-71. PubMed ID: 25552920
[TBL] [Abstract][Full Text] [Related]
35. Epithelial-to-mesenchymal transition in cancer: complexity and opportunities.
Zhang Y; Weinberg RA
Front Med; 2018 Aug; 12(4):361-373. PubMed ID: 30043221
[TBL] [Abstract][Full Text] [Related]
36. Epithelial-to-mesenchymal transition leads to disease-stage differences in circulating tumor cell detection and metastasis in pre-clinical models of prostate cancer.
Lowes LE; Goodale D; Xia Y; Postenka C; Piaseczny MM; Paczkowski F; Allan AL
Oncotarget; 2016 Nov; 7(46):76125-76139. PubMed ID: 27764810
[TBL] [Abstract][Full Text] [Related]
37. miR-195 Inhibits EMT by Targeting FGF2 in Prostate Cancer Cells.
Liu C; Guan H; Wang Y; Chen M; Xu B; Zhang L; Lu K; Tao T; Zhang X; Huang Y
PLoS One; 2015; 10(12):e0144073. PubMed ID: 26650737
[TBL] [Abstract][Full Text] [Related]
38. EMT as the ultimate survival mechanism of cancer cells.
Tiwari N; Gheldof A; Tatari M; Christofori G
Semin Cancer Biol; 2012 Jun; 22(3):194-207. PubMed ID: 22406545
[TBL] [Abstract][Full Text] [Related]
39. Predictive value of epithelial-mesenchymal-transition (EMT) signature and PARP-1 in prostate cancer radioresistance.
Stark TW; Hensley PJ; Spear A; Pu H; Strup SS; Kyprianou N
Prostate; 2017 Dec; 77(16):1583-1591. PubMed ID: 29063620
[TBL] [Abstract][Full Text] [Related]
40. Evidence of epithelial to mesenchymal transition associated with increased tumorigenic potential in an immortalized normal prostate epithelial cell line.
Marian CO; Yang L; Zou YS; Gore C; Pong RC; Shay JW; Kabbani W; Hsieh JT; Raj GV
Prostate; 2011 May; 71(6):626-36. PubMed ID: 20945502
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
